About 318 results

ALLMedicine™ Intermediate Uveitis Center

Research & Reviews  114 results

Fitness to Serve in the Armed Forces and Internal Medicine: A Retrospective Study.
Military Medicine; Lhaiba M, Caré W et. al.

Apr 13th, 2022 - Assessment of the medical fitness to serve in the armed forces has two objectives: to prevent the military operations from being jeopardized by a medical issue, and to protect soldiers from the sequelae of diseases that could become complicated in...

Dynamic changes of Elschnig pearls posterior capsule opacification.
BMJ Case Reports; Basiron SF', Khaw AML et. al.

Mar 31st, 2022 - An adolescent female with underlying bilateral pseudophakia and idiopathic intermediate uveitis had reduced visual acuity due to posterior capsule opacification (PCO). The rapid progression and different morphological formations of Elschnig pearls...

Long-Term Outcomes of Pediatric Idiopathic Intermediate Uveitis.
American Journal of Ophthalmology; AlBloushi AF, Solebo AL et. al.

Nov 16th, 2021 - To describe the course of childhood-onset intermediate uveitis without associated systemic disease, and investigate determinants of outcomes. A retrospective clinical cohort study METHODS: This study was conducted in an institutional setting. A to...

Blau syndrome: a case report from Palestine.
Pediatric Rheumatology Online Journal; Iriqat S, Safieh MA et. al.

Sep 2nd, 2021 - This case study documents the first familial case of Blau syndrome (BS) in Palestine characterized with mutation in CARD15/NOD2. Eighteen years old female was initially misdiagnosed with Juvenile idiopathic arthritis (JIA). The patient had been on...

see more →

Guidelines  1 results

Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tuber...
Ophthalmology Agrawal R, Testi I et. al.

Jul 1st, 2020 - The Collaborative Ocular Tuberculosis Study (COTS), supported by the International Ocular Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Society, set up an international, expert-led consensus project to de...

see more →

Clinicaltrials.gov  4 results

Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Jul 7th, 2021 - A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)

Mar 26th, 2021 - Objective: Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications for uveitis can cause significant adverse effects and many patients continue to experience d...

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

Mar 29th, 2013 - Anterior uveitis is a disorder of the eye associated with intraocular inflammation of the anterior portion of the uvea, particularly the iris and/or ciliary body. It is distinct from other iterations of uveitis such as posterior, diffuse and inter...

Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis

Dec 3rd, 2012 - Deuter et al were the first to show the anti-edematous effect of interferon alpha on inflammatory macular edema (Deuter C. M. E., Kötter I., Günaydin I., Zierhut M. Treatment of the Cystoid Macular Oedema in Behçet's Disease with Interferon Alfa-2...

see more →

News  6 results

Two uveitis treatment options yield similar success
Heidi Splete

Sep 10th, 2019 - Approximately two-thirds of adults with uveitis achieved inflammation control after 6 months on either methotrexate or mycophenolate alongside a reduction in corticosteroid use in an international, multicenter, open-label, randomized trial. “The f.

Sustained Drug-Delivery Tech Shows Promise

Nov 19th, 2017 - Development of technologies for sustained drug delivery is a topic of great interest among retina specialists, considering the number of chronic conditions that are managed with repeated intravitreal injections. Products in this category are alrea...

FDA Clears Adalimumab (Humira) for Uveitis

Jul 1st, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Clears Adalimumab (Humira) for Uveitis

Jul 1st, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Grants Orphan Drug Status to Gevokizumab

Aug 29th, 2012 - August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL-1β), for the treatment of noninfectious intermediate u...

see more →

Patient Education  2 results see all →